يعرض 1 - 10 نتائج من 68 نتيجة بحث عن '"AP-1 complex"', وقت الاستعلام: 1.64s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Centre de référence Maladies Rares CLAD-Ouest Rennes, Universidad Autónoma de Madrid (UAM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Department of Microbiology, Immunology and Transplantation Leuven, Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven), University Hospitals Leuven Leuven, Laboratoire National de Santé Luxembourg (LNS), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Institut du Thorax Nantes, Antwerp University Hospital Edegem (UZA), Centre Hospitalier de Luxembourg Luxembourg (CHL), Geroscience and rejuvenation research center (RESTORE), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang Rennes (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Universitat Pompeu Fabra Barcelona (UPF), Research reported in this publication was supported by the CatalonianDepartment of Health (URDCAT: Grant SLT002/16/00174) and the ENoD Programme of CIBERER(ER16P08), Instituto de Salud Carlos III. Selket Delafontaine is supported by the personal FWO Grant11F4421N. Isabelle Meyts is a Senior Clinical Investigator at the Research Foundation – Flanders, andis supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 GrantC16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and bythe Jeffrey Modell Foundation. Part of this work was supported by a grant from the Spanish Ministryof Science and Innovation (PID2019-105620RB-I00/AEI/10.13039/501100011033). The project hasalso received funding from the European Research Council (ERC) under the European Union’s Horizon2020 research and innovation programme (grant agreement No. 948959). This work is supported byERN-RITA.LAPJ is founding partner and scientific advisor of qGenomics Laboratories. The remaining authorsdeclare no potential conflict of interest.

    المصدر: ISSN: 1098-3600.

  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7

    المساهمون: Human Genetics, ACS - Pulmonary hypertension & thrombosis, ANS - Complex Trait Genetics, Faculteit Medische Wetenschappen/UMCG, Clinical Genetics

    المصدر: American Journal of Human Genetics, 108, 1330-1341
    American journal of human genetics, 108(7), 1330-1341. Cell Press
    Am J Hum Genet
    American Journal of Human Genetics, 108, 7, pp. 1330-1341
    American Journal of Human Genetics, 108(7), 1330-1341. CELL PRESS
    American Journal of Human Genetics, 108(7), 1330-1341. Cell Press
    Am. J. Hum. Genet. 108, 1330-1341 (2021)

    وصف الملف: application/pdf

  8. 8

    المساهمون: Generalitat de Catalunya, CHU Pontchaillou [Rennes], Centre de référence Maladies Rares CLAD-Ouest [Rennes], Universidad Autónoma de Madrid (UAM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Department of Microbiology, Immunology and Transplantation [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), University Hospitals Leuven [Leuven], Laboratoire National de Santé [Luxembourg] (LNS), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut du Thorax [Nantes], Antwerp University Hospital [Edegem] (UZA), Centre Hospitalier de Luxembourg [Luxembourg] (CHL), Geroscience and rejuvenation research center (RESTORE), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Universitat Pompeu Fabra [Barcelona] (UPF), Research reported in this publication was supported by the CatalonianDepartment of Health (URDCAT: Grant SLT002/16/00174) and the ENoD Programme of CIBERER(ER16P08), Instituto de Salud Carlos III. Selket Delafontaine is supported by the personal FWO Grant11F4421N. Isabelle Meyts is a Senior Clinical Investigator at the Research Foundation – Flanders, andis supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 GrantC16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and bythe Jeffrey Modell Foundation. Part of this work was supported by a grant from the Spanish Ministryof Science and Innovation (PID2019-105620RB-I00/AEI/10.13039/501100011033). The project hasalso received funding from the European Research Council (ERC) under the European Union’s Horizon2020 research and innovation programme (grant agreement No. 948959). This work is supported byERN-RITA.LAPJ is founding partner and scientific advisor of qGenomics Laboratories. The remaining authorsdeclare no potential conflict of interest.

    المصدر: Genetics in Medicine
    Genetics in Medicine, 2022, 24 (12), pp.2475-2486. ⟨10.1016/j.gim.2022.09.002⟩
    Genetics in medicine

  9. 9
    رسالة جامعية

    المؤلفون: Tavares, Lucas Alves

    مرشدي الرسالة: Silva, Luis Lamberti Pinto da

    مصطلحات موضوعية: 2 depletion, acts in the CD4 down-regulation induced by Nef. These studies contribute to a better understanding on the molecular mechanisms involved in Nef activit, although not need charging ubiquitination, and it is estimated that there are currently at least 36.9 million people infected with the virus. During the replication cycle, and only the AP-1 variant comprising ?2, another subunit of AP-1, AP-1, AP-1 subunits. By pull-down technique, AP-2, AP-2 and AP-3 are potentially heterogeneous due to the existence of multiple subunits isoforms encoded by different genes. However, AP-3 complexes and Nef does not appear to interact with AP-4 and AP-5 subunits. However, being an important protein in the endo-lysosomal system. Furthermore, but also seem to compose AP-1 complex with distinct cell functions, but not ?1, but not ?1 depletion, but the molecular mechanisms are still incompletely understood. Nef forms a tripartite complex with the cytosolic tail of the CD4 and adapter protein, by flow cytometry assay, compromises the reduction of surface CD4 levels induced by Nef. Immunofluorescence microscopy analysis also revealed that ?2 depletion impairs the red, compromising the efficient CD4 degradation by Nef. Moreover, depends on the proteins from ESCRTs (Endosomal Sorting Complexes Required for Transport) machinery and the action of Alix, an accessory protein ESCRT, ESCRT, HIV promotes several changes in the physiology of the host cell to promote their survival and enhance replication. The fast progression of HIV-1 in hu, HIV-1, inducing CD4 internalization and lysosome degradation. Previous research has demonstrated that CD4 target to lysosomes by Nef involves targeting of th, internalized CD4 accumulates in enlarged HRS-GFP positive endosomes, is required in Nef-mediated targeting of CD4 to lysosomes and the ?2 participation in this process is conserved by Nef from different viral strains. F, MVB, Nef, not ?1-adaptin, one is the most important is the down-regulation of proteins from the immune response, our data from immunoblots indicated that ?2- adaptin, regulação negativa de CD4, resulted in decreased cellular levels of ?1 and ?2 and, resulting in CD4 accumulation in primary endosomes. Knockdown of ?1A, such as the CD4 receptor. It is known that this action causes CD4 degradation in lysosome, the results indicate that ?-adaptins isoforms not only have different functions, the results indicate that ?2-adaptin is a molecule that is essential for CD4 targeting by Nef to ESCRT/MVB pathway, The Human Immunodeficiency Virus (HIV) is the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). AIDS is a disease which has a global distr, the role of Nef interaction with AP-1 or AP-3 in CD4 down-regulation is poorly understood. Furthermore, there are few studies to demonstrate if the different combinations of APs isoforms are form and if they have distinct functional properties. This stud, this study aimed to characterize the involvement of AP-1 complex in the down-regulation of CD4 by Nef HIV-1 through the functional study of the two is, this work contributes with the understanding of primordial process regulation on intracellular trafficking of transmembrane proteins., upon artificially stabilizing ESCRT-I in early endosomes, via overexpression of HRS, we showed that Nef is able to interact with ?2. In addition, where co-localize with ?2. Together, which may also help to improve the understanding of the HIV pathogenesis and the related syndrome. In addition, y1-adaptina, y2-adaptina

    وصف الملف: application/pdf

  10. 10